Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | C9X3R | IM / LA |
Patient developed a raised, red area starting at administration site. This increased in diameter over the period of 3 days. Vaccine was given 9/30 & pt was seen 10/3 for concerns of reaction. This area in question also developed a "tail" at the bottom of the site. Area on left deltoid after administration developed a red, raised area which was hot to the touch, painful & patient complained of extreme itching sensation. 9/30/25 vaccine administered 10/2/25 patient report area where vaccine was given developed the size of a "softball" per patient. She was asked to stop by the PCP office prior to the weekend. 10/3/25 Patient stopped into PCP office and area in question was still very red, raised & warm to the touch. Official measurements of area within vaccine administration site & "tail" that had developed overnight (from 10/2 to 10/3) are as such: -area surrounding vaccine site 4.5 in (H) x 3.75 in (W) -tail that developed at bottom of area: 2.5 in long
N/A
HTN, CAD, afib, HLD, heart failure
Aspirin Ec Low Dose 81 mg; Co Q-10 10 mg capsule; fluorometholone 0.1% eye drops, suspension; fluorouracil 5% topical cream; furosemide 20 mg tablet; hydralazine 25 mg tablet; Jardiance 10 mg tablet; metoprolol succinate ER 50 mg tablet, ex
Cephalexin, lisinopril, PCN, meperidine, clarithromycin
N/A > measurements of area taken 10/3/25